Replies to post #279785 on Amarin Corp Plc (AMRN)

[jessellivermore]

KIWI..

Teva's settlement allows them to enter the market in 2029..or perhaps earlier under certain circumstances. Doubt those mean they will enter this year..

From Amarin...
In the lawsuit, Amarin alleges that the generic forms of Vascepa adverse parties seek to market in the United States infringe upon multiple issued patents owned by Amarin. As part of the settlement agreement, Teva may first begin selling its generic version of Vascepa in the United States on August 9, 2029, or earlier under certain customary circumstances. The agreement is subject to a required review by the U.S. Federal Trade Commission and the U.S. Department of Justice.

G. Any idea what certain customary circumstance might be?

":>) JL